Leone D. Patterson
Known title: EVP, Chief Bus & Fin OfficerCIK: 0001233539
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Tenaya Therapeutics noted among health‑care stocks moving intraday. Tenaya Therapeutics was listed among twelve health‑care stocks that showed notable intraday movement on Wednesday, according to Benzinga. The activity reflects broader sector momentum and comes while the stock is in oversold territory (RSI 19.6) and near its $0.68 support level.
Transaction History
| ZYME | ▲ Buy | Grant | 459 | $5K | 1/6/2026 | View on chart |
| TNYA | ▲ Buy | Grant | 35,000 | $0 | 2/23/2024 | View on chart |
| TNYA | ▼ Sell | Open Market | 5,201 | $30K | 2/16/2024 | View on chart |
| TNYA | ▼ Sell | Open Market | 4,452 | $17K | 8/16/2023 | View on chart |
| TNYA | ▲ Buy | Grant | 30,000 | $0 | 2/15/2023 | View on chart |
| TNYA | ▲ Buy | Grant | 35,000 | $0 | 2/15/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
ZYME News Highlights Potential Undervaluation and Raised Price Target
Recent coverage notes that Zymeworks may be about 39% undervalued based on its 2026 revenue guidance and the recent appointment of a chief investment officer. Truist Securities also kept its rating and lifted its price target to $34, reflecting continued confidence in the company's outlook.
ZYME News Highlights Potential Undervaluation and Raised Price Target. Recent coverage notes that Zymeworks may be about 39% undervalued based on its 2026 revenue guidance and the recent appointment of a chief investment officer. Truist Securities also kept its rating and lifted its price target to $34, reflecting continued confidence in the company's outlook.